Metabolic monitoring schedule
Enter the antipsychotic and the start date. The tool prints the ADA/APA metabolic monitoring schedule with dated visits: weight and BMI at baseline, weeks 4, 8, and 12, then quarterly; fasting glucose or HbA1c and a lipid panel at baseline, three months, then at least annually. It's the same schedule that lives in the drug pages, restated with real dates so you can hand it to a patient or add it to a chart.
Monitoring schedule
Choose an antipsychotic and a start date.
Reference data current as of June 8, 2026. Sources: ADA/APA Consensus Statement on Antipsychotic Drugs and Obesity and Diabetes; Carolan A et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain. Schizophrenia Bulletin 2025.
How to read this
Higher-risk antipsychotics (olanzapine, clozapine) often warrant tighter cadence than the ADA/APA baseline schedule (many practices repeat glucose and lipids every three to six months instead of annually). The Carolan guideline recommends starting metformin at the same time as olanzapine or clozapine to blunt weight gain. Any deviation from the schedule shown here belongs with the licensed prescriber who knows the patient.
About this tool
Metabolic side effects are the leading cause of premature mortality in patients with schizophrenia and bipolar disorder. Weight gain, dyslipidemia, insulin resistance, and type 2 diabetes are all elevated in this population, and second-generation antipsychotics contribute directly. The 2004 American Diabetes Association / American Psychiatric Association / American Association of Clinical Endocrinologists / North American Association for the Study of Obesity consensus statement established a monitoring cadence that remains the reference standard.
The tool takes a drug name and a start date and returns dated appointments for baseline labs, weight and BMI checks at weeks 4, 8, and 12, quarterly weight and BMI thereafter, and annual glucose or HbA1c plus lipid panel. Drug-specific risk tier (higher for olanzapine and clozapine; medium for quetiapine and risperidone; lower for aripiprazole, brexpiprazole, cariprazine, ziprasidone, lurasidone, and lumateperone) is factored into the recommended monitoring frequency.
For patients starting high-risk antipsychotics (olanzapine, clozapine), the schedule flags concurrent metformin initiation per the comorbidity medication selection guide and the Aoife Carolan et al. meta-analysis in Schizophrenia Bulletin. Co-commencement of metformin at treatment start reduces weight gain compared to waiting until weight gain occurs.
Two clinical scenarios worth being explicit about. First, patients who develop new-onset diabetes on an antipsychotic often benefit from a switch to a lower-metabolic-risk drug in the same class rather than adding oral hypoglycemics on top of the causative agent. Second, patients on long-term high-dose olanzapine or clozapine often have irreversible weight gain and metabolic changes; the monitoring is not a way to catch reversible disease, it is a way to intervene early before the damage is fixed. The full clinical write-up is in the atypical antipsychotics class overview.
Common questions
- What is the ADA/APA metabolic monitoring schedule?
The 2004 ADA/APA/AACE/NAASO consensus recommended baseline personal and family history, weight and BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel before starting any atypical antipsychotic. Weight and BMI are then rechecked at weeks 4, 8, and 12, and at least quarterly thereafter. Fasting glucose and lipid panel are rechecked at 3 months, then at least annually. Blood pressure and waist circumference are rechecked at 3 months, then annually. This is the reference standard and is what the tool generates dates for.
- Which antipsychotics carry the highest metabolic risk?
Olanzapine and clozapine consistently show the highest weight gain and metabolic syndrome risk in head-to-head trials and observational data. Quetiapine and risperidone sit in the middle. Aripiprazole, brexpiprazole, cariprazine, ziprasidone, lurasidone, and lumateperone show lower weight gain risk. Cobenfy (xanomeline-trospium) showed no significant weight gain in the EMERGENT trials. This tool tiers the monitoring frequency accordingly.
- When is metformin added to prevent antipsychotic-induced weight gain?
The Carolan et al. (Schizophrenia Bulletin) meta-analysis supports co-commencement of metformin with high-risk antipsychotics (olanzapine, clozapine) to blunt weight gain and metabolic dysregulation. The recommendation is to start metformin at the same time as the antipsychotic in patients starting a high-risk drug, rather than waiting until weight gain occurs. The tool flags this on the schedule for high-risk drugs. See the olanzapine drug page for full context.
- Do first-generation antipsychotics need metabolic monitoring?
Yes, though the risk profile differs. Chlorpromazine, thioridazine, and other low-potency first-generation antipsychotics carry substantial weight gain risk (similar to atypicals). High-potency first-generation drugs (haloperidol, fluphenazine, perphenazine) have lower metabolic risk but still warrant baseline and periodic monitoring given the population context (schizophrenia patients have elevated cardiovascular mortality risk regardless of medication). The ADA/APA schedule applies to any antipsychotic, atypical or typical, in current practice.
- How often should HbA1c be checked?
The 2004 consensus specifies fasting glucose at baseline, 3 months, then annually. Many contemporary clinicians substitute HbA1c because it does not require fasting and reflects 8 to 12 weeks of glycemic control. HbA1c is not in the original consensus but is a reasonable practical substitute. In patients with impaired fasting glucose, prediabetes, or a family history of type 2 diabetes, more frequent monitoring is appropriate.
- Is this schedule a personalized medical recommendation?
No. It generates dates from a published guideline. It does not account for patient-specific factors like family history, prior metabolic events, baseline labs, concurrent medications, or diet and exercise context. Every prescribing decision, including monitoring cadence, belongs with the licensed clinician who has the full clinical picture. This tool is a scheduling aid over a published standard.